The Full Wiki

More info on Adrenergic uptake inhibitor

Adrenergic uptake inhibitor: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


(Redirected to Norepinephrine reuptake inhibitor article)

From Wikipedia, the free encyclopedia

A norepinephrine reuptake inhibitor (NRI, NERI) or adrenergic reuptake inhibitor (ARI), is a type of drug which acts as a reuptake inhibitor for the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline) by blocking the action of the norepinephrine transporter (NET). This in turn leads to increased extracellular concentrations of norepinephrine and epinephrine and therefore an increase in adrenergic neurotransmission.



NRIs may be used in the clinical treatment of attention-deficit hyperactivity disorder (ADHD), narcolepsy, and fatigue or lethargy as stimulants, obesity as anorectics or appetite suppressants for weight loss purposes, as well as mood disorders such as major depressive disorder (MDD) as antidepressants, nasal or sinus congestion as decongestants, nocturnal enuresis or "bedwetting", hypotension and/or orthostatic hypotension as vasopressors, and both as augmentations and to offset some of the side effects of certain other drugs like the selective serotonin reuptake inhibitors (SSRIs) such as sexual dysfunction.




NRIs can induce a wide range of psychological and physiological effects, including the following:


It should be noted, however, that many of these properties are dependent on whether the NRI in question is capable of crossing the blood-brain-barrier (BBB). Those that do not will only produce peripheral effects.


At very high doses characterized by overdose, a number of symptoms may come to prominence, as well as hypertensive crisis, including the following:



In contrast to dopamine reuptake inhibitors (DRIs) such as cocaine and methylphenidate, NRIs without DRI properties which do not affect dopamine are incapable of inducing significant rewarding effects and are not self-administered in rodents, and as a result, they have a negligible abuse potential in comparison.[1][2]

List of NRIs

Pharmaceutical Drugs
Dietary Supplements
Street Drugs
Research Chemicals
Natural Sources

See also


  1. ^ Wee S, Woolverton WL (September 2004). "Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine". Drug and Alcohol Dependence 75 (3): 271–6. doi:10.1016/j.drugalcdep.2004.03.010. PMID 15283948. 
  2. ^ Gasior M, Bergman J, Kallman MJ, Paronis CA (April 2005). "Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys". Neuropsychopharmacology 30 (4): 758–64. doi:10.1038/sj.npp.1300593. PMID 15526000. 
  3. ^ Zhao G, Li S, Qin GW, Fei J, Guo LH (July 2007). "Inhibitive effects of Fructus Psoraleae extract on dopamine transporter and noradrenaline transporter". Journal of Ethnopharmacology 112 (3): 498–506. doi:10.1016/j.jep.2007.04.013. PMID 17555897. 


Got something to say? Make a comment.
Your name
Your email address